No Data
No Data
ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ImmunityBio | 10-Q: Quarterly report
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment
ImmunityBio (IBRX) shares rose almost 10% in recent trading after the company shared the completion and qualification Tuesday of the drug substance for filling vials and finishing packaging enough for
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday.Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply during Tuesday's session following upbeat quarterly ear
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA productImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk,
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)
No Data
2deMoonmoon : bad
Invest Long ✓OP : bad outlook?